Rani raises cash for 'holy grail' of oral formulations for biologics

Rani Therapeutics completed a Series B funding round to finance technology that's designed to convert biologics into pills, which could give pharmaceutical companies a competitive advantage and extend the patent lives of blockbuster injectable drugs, according to the company's chairman and CEO Mir Imran.

Rani Therapeutics completed a Series B funding round to finance technology that's designed to convert biologics into pills, which could give pharmaceutical companies a competitive advantage and extend the patent lives of blockbuster injectable drugs, according to the company's chairman and CEO Mir Imran.

Company

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Alimentary/Metabolic

More from Therapeutic Category